Kelly R McMahon
Overview
Explore the profile of Kelly R McMahon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang R, McMahon K, Wang S, Chui H, Lebel A, Lee J, et al.
Kidney360
. 2024 Apr;
5(6):821-833.
PMID: 38668904
No abstract available.
2.
Chui H, McMahon K, Rassekh S, Schultz K, Blydt-Hansen T, Mammen C, et al.
Pediatr Nephrol
. 2023 Jun;
39(1):269-282.
PMID: 37365422
Background: Cisplatin is associated with acute kidney injury (AKI) and electrolyte abnormalities. Urine tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP-7) may be early cisplatin-AKI...
3.
McMahon K, Lebel A, Rassekh S, Schultz K, Blydt-Hansen T, Cuvelier G, et al.
Pediatr Nephrol
. 2022 Oct;
38(5):1667-1685.
PMID: 36260162
Background: Few studies describe acute kidney injury (AKI) burden during paediatric cisplatin therapy and post-cisplatin kidney outcomes. We determined risk factors for and rate of (1) AKI during cisplatin therapy,...
4.
McMahon K, Chui H, Rassekh S, Schultz K, Blydt-Hansen T, Mammen C, et al.
Kidney360
. 2022 Apr;
3(1):37-50.
PMID: 35368557
Background: Few studies have described associations between the AKI biomarkers urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) with AKI in cisplatin-treated children. We aimed to describe excretion...
5.
Association of Urine Platinum With Acute Kidney Injury in Children Treated With Cisplatin for Cancer
Lebel A, Chui H, McMahon K, Lim Y, Macri J, Wang S, et al.
J Clin Pharmacol
. 2021 Feb;
61(7):871-880.
PMID: 33599997
Cisplatin is a chemotherapeutic agent highly excreted in urine and known to cause acute kidney injury (AKI). As AKI diagnosis by serum creatinine (SCr) is usually delayed, endeavors for finding...
6.
McMahon K, Rassekh S, Schultz K, Blydt-Hansen T, Cuvelier G, Mammen C, et al.
JAMA Netw Open
. 2020 May;
3(5):e203639.
PMID: 32383745
Importance: Few multicenter pediatric studies have comprehensively described the epidemiologic characteristics of cisplatin-associated acute kidney injury using standardized definitions. Objective: To examine the rate of and risk factors associated with...
7.
McMahon K, Harel-Sterling M, Pizzi M, Huynh L, Hessey E, Zappitelli M
Pediatr Nephrol
. 2018 Sep;
33(12):2311-2320.
PMID: 30218190
Background: Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h...
8.
Sterling M, Al-Ismaili Z, McMahon K, Piccioni M, Pizzi M, Mottes T, et al.
Pediatr Blood Cancer
. 2017 Apr;
64(10).
PMID: 28417544
Background: Cisplatin (Cis), carboplatin (Carb), and ifosfamide (Ifos) are common nephrotoxic chemotherapies. Biomarkers of tubular injury may allow for early acute kidney injury (AKI) diagnosis. Procedure: We performed a two-center...
9.
McMahon K, Rassekh S, Schultz K, Pinsk M, Blydt-Hansen T, Mammen C, et al.
Can J Kidney Health Dis
. 2017 Mar;
4:2054358117690338.
PMID: 28270931
Background: Childhood cancer survivors experience adverse drug events leading to lifelong health issues. The Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) team was established to validate...